SUMMARY -Th e purpose of this review is to analyze current medical strategies in the prevention of ovarian hyperstimulation syndrome (OHSS) during ovarian stimulation for in vitro fertilization. Owing to contemporary preventive measures of OHSS, the incidence of moderate and severe forms of the syndrome varies between 0.18% and 1.40%. Although none of medical strategies is completely eff ective, there is high-quality evidence that replacing human chorionic gonadotropin (hCG) by gonadotropin-releasing hormone (GnRH) agonists after GnRH antagonists and moderate-quality evidence that GnRH antagonist protocols, dopamine agonists and mild protocols reduce the occurrence of OHSS. Among various GnRH agonists, buserelin 0.5 mg, triptorelin 0.2 mg and leuprolide acetate (0.5-4 mg) have been mostly utilized. Although GnRH trigger is currently regarded as the best tool for OHSS prevention, intensive luteal support with exogenous administration of estradiol and progesterone or low-dose hCG on the day of oocyte retrieval or on the day of GnRH agonist trigger are required to achieve optimal conception rates due to early luteolysis. Among currently available dopamine agonists, cabergoline, quinagolide and bromocriptine are the most common drugs that should be used for prevention of both early and late OHSS. Mild stimulation protocols off er attractive option in OHSS prevention with satisfactory pregnancy rates.
Introduction
Ovarian hyperstimulation syndrome (OHSS) is the most serious iatrogenic complication of controlled ovarian stimulation (COS), which can vary from mild illness to severe, potentially life-threatening disease. Th e syndrome almost always occurs a few days after receiving human chorionic gonadotropin (hCG) (early OHSS), or later (late OHSS), which depends on the occurrence of endogenous hCG 1 . Although OHSS may occasionally occur spontaneously between eight and twelve weeks of pregnancy or with a follicle-stimulating hormone (FSH) producing pituitary adenoma, the great majority of cases are iatrogenic due to ovulation induction in women undergoing assisted reproductive techniques (ART) 2 . According to the latest European Society of Human Reproduction and Embryology (ESHRE) report, the incidence of OHSS ranges from 0.18% to 1.40% of stimulated in vitro fertilization (IVF) cycles in European countries 3 . Although the pathophysiology of the syndrome is not entirely clear, it is assumed that the vasoactive substances secreted by ovaries under hCG stimulation may play a key role in increasing capillary permeability observed in OHSS. Of all the diff erent vasoactive cy-tokines, vascular endothelial growth factor (VEGF) is the principal mediator and is most responsible for vascular hyperpermeability. A generalized capillary leak and acute shift of protein-rich fl uid from the intravascular compartment into the third space may lead to hypoproteinemia, oliguria, acute renal failure and increased blood viscosity with changes in coagulation parameters resulting in severe morbidity and possible mortality due to thromboembolic events 4 . Th erefore, good preventive strategies may be required, which would enable a fair chance to achieve safe pregnancy and to reduce or avoid the occurrence of the syndrome as a life-threatening complication of IVF treatment. Although various strategies have been proposed and have been tried to prevent this serious complication, none was found to be completely eff ective. Th e key to prevent OHSS is recognition of risk factors for the syndrome and the experience with ovulation stimulation. Primary prevention includes identifi cation of patients at high risk of OHSS such as younger age, a history of good response to gonadotropins, thin women, poly cystic ovary syndrome (PCOS) and history of aller gies. Ovulation induction protocols should be individually tailored with minimal dose and duration of gonadotropins combined with gonadotropin-releasing hormone (GnRH) antagonist or in vitro oocyte maturation, and carefully monitored. Secondary prevention represents all interventions for the early control of OHSS during ovulation induction including cycle cancellation, coasting, trigger ovulation by low doses of hCG or by alternative agents, cryopreservation of oocytes/embryos and adequate luteal phase support 5, 6 . Current evidence demonstrates that age, antral follicle count and anti-müllerian hormone levels have proved as the best methods of predicting high ovarian response before starting COS. Although estradiol (E2) levels were previously less reliable in prediction of OHSS during ovulation stimulation 7 , currently E2 concentrations, the number of medium/large follicles on the day of hCG and the number of retrieved oocytes are regarded as reliable markers of high ovarian response 8 . Th ere is high-quality evidence that replacing hCG by GnRH agonists and moderate-quality evidence that antagonist protocols, dopamine agonists and mild stimulation reduce the occurrence of OHSS. However, evidence for the eff ect of other interventions is of low/very low quality 8 . Accordingly, the objective of the present review is to analyze the eff ectiveness and safety of medical strategies that currently may be justifi ably utilized in the prevention of OHSS.
GnRH Agonists
Gonadotropin-releasing hormone agonists trigger instead of hCG in the context of OHSS prevention has been used for >25 years. In its fi rst decade, it did not gain popularity because it cannot work in GnRH agonist-based ovarian stimulation protocols. Although GnRH agonist initially binds and activates GnRHreceptors inducing a transient rise in gonadotropins, known as a fl are-up, this is followed by a state of pituitary desensitization, resulting in a decrease in GnRH receptors and diminished response to GnRH stimulation. However, the GnRH antagonist occupies the GnRH receptor competitively without causing downregulation. Th e antagonistic eff ects of GnRH antagonists may be overcome by GnRH agonists, as GnRH agonists have a greater affi nity for the GnRH receptor than GnRH antagonists. By injecting a single bolus of GnRH agonist, the antagonist is displaced from the receptor by the GnRH agonist, which activates the receptor, inducing a fl are-up of gonadotropins that accumulate during GnRH antagonist protocols and effectively stimulating the fi nal oocyte maturation and ovulation [9] [10] [11] . Although a single bolus of hCG at midcycle has been the gold standard for triggering fi nal oocyte maturation and ovulation in ART cycles, it seems that the GnRH agonist trigger may allow a more physiological surge of both luteinzing hormone (LH) and FSH. Th e short duration of the LH surge with the GnRH agonist trigger of approximately thirty-four hours has been shown to be benefi cial for preventing OHSS in GnRH antagonist IVF cycles, when compared with the prolonged elevation of hCG (≥6 days) after exposure to an hCG bolus 12 . Although an advantage of the GnRH agonist trigger is the ability to retrieve oocytes in high responders with a markedly reduced risk of OHSS, the induction of early luteolysis after the GnRH agonist trigger represents a problem that requires the use of aggressive steroidal luteal support or low-dose hCG to allow successful fresh embryo transfer (ET) and live birth. Early luteolysis following COS and GnRH agonist is likely due to supraphysiological steroid hormone concentrations inhibiting the LH secre tion via negative feedback at the level of the hy pothalamic-pituitary-gonadal axis and short-er duration of the endogenously induced LH surge with a potential weaker activation of the LH/hCG receptor 13 . Although diff erent GnRH agonists have been used in GnRH antagonist cycles for the fi nal oocyte maturation in high-responders, no universal consensus has been defi ned regarding the optimal agonist kind and dose, and there is no report evaluating the impact of diff erent agonists on cycle outcomes. Among various GnRH agonists, buserelin 0.5 mg 14 , triptorelin 0.2 mg 15, 16 and leuprolide acetate (0.5-4 mg) 17, 18 have been utilized and almost all studies compared the outcomes of GnRH agonist triggered cycles with the cycles triggered with hCG. Most previous studies have reported successful oocyte maturation with 0.2-0.3 mg triptorelin, 0.5 mg buserelin and 1 mg leuprolide acetate [14] [15] [16] 19 . Since there is no established triggering dose, GnRH agonists may be eff ective even at lower doses because 0.1 mg triptorelin eff ectively induces fi nal oocyte maturation in IVF cycles similarly as standard doses. Th e rate of retrieved oocytes per follicle (89%) and fertilization rate (71%) support the use of lower doses of GnRH agonists in clinical practice 16 . Although higher doses of agonists for the fi nal oocyte maturation have a potential to result in higher gonadotropin surge amplitude and improve the oocyte quantity, the mean number of retrieved oocytes varies and no clear benefi t has been demonstrated by this approach 18 . Since the possible standardization for GnRH agonist trigger criteria that will yield optimal outcomes have not yet been established, some authors used increased estradiol levels as a criterion 20 , whereas others assessed only excess number of available follicles during the late follicular phase of ovarian stimulation 21 . Th e criteria for GnRH agonist triggering for the patients at high risk of OHSS characterized by a high number of follicles (>12) measuring ≥12 mm and/or high serum E2 levels (≥4000 pg/mL) have been suggested 18 . According to results from several studies in the last decade in OHSS high risk patients, the GnRH agonist for ovulation triggering signifi cantly reduces or almost elimi nates the incidence of OHSS and therefore GnRH agonist trigger is the best tool for OHSS prevention 3, [22] [23] [24] . GnRH agonist triggering is a valid alternative to hCG triggering, resulting in elimination of OHSS and no other pre vention strategy comes close to this result 25 . However, several anecdotal cases of severe OHSS, even after GnRH agonist triggering combined with freezing all embryos in GnRH antagonist cycles have been published and in these cases of extreme hyper-responders other prevention strategies should be considered 26, 27 . Th erefore, clinicians should be aware that severe early OHSS could rarely occur even after GnRH agonist trigger instead of hCG, despite the fact that induction of fi nal oocyte maturation with GnRH agonist signifi cantly reduces the risk of OHSS. Moreover, an additional risk of late OHSS is possible if pregnancy occurs 28 . Despite acceptable cycle parameters following agonist-triggered cycles, a recently updated Cochrane review has reported that the use of GnRH agonist trigger instead of hCG in fresh autologous cycles was associated with a lower live birth rate, lower ongoing pregnancy rate and higher rate of early miscarriage. However, in donorrecipient cycles, the use of GnRH agonists resulted in a lower incidence of OHSS, with no evidence of difference in live birth rate. Th erefore, GnRH agonist could be useful for women who choose to avoid fresh transfers, women who donate oocytes to recipients, or women who wish to freeze their eggs for later use in the context of fertility preservation 29 . Unfortunately, data from studies in the review were not comparable due to diff erent luteal phase protocols used; therefore, the analysis missed the fact that luteal support is the factor which aff ects pregnancy rate and not the use of GnRH agonist trigger for fi nal oocyte maturation 30 . Th erefore, a meaningful comparison between GnRH agonist and hCG trigger must be confi ned to outcome measures that are not aff ected by the luteal support used 31 . Unfortunately, standard luteal phase support after GnRH agonist triggering has been reported to be associated with lower conception rates due to corpus luteum dysfunction. Aiming to attain an adequate luteal phase for a fresh embryo transfer and to improve IVF outcomes, the luteal phase support protocols after GnRH agonist trigger have emerged over recent years by using several diff erent concepts. Th e American concept which relies mostly on intensive luteal support with aggressive exogenous administration of E2 and progesterone is eff ective in maintaining optimal conception rates in patients with peak E2 levels >4000 pg/ mL. Th e European approach promotes the production of endogenous steroids by the corpus luteum via exogenous supplementation of a small dose of hCG on the day of oocyte retrieval or on the day of GnRH agonist trigger ('dual trigger'). However, patients with peak E2 levels <4000 pg/mL may benefi t from dual trigger with GnRH agonist and 1000 IU hCG with intensive luteal phase support to optimize conception rates while still avoiding signifi cant OHSS 32, 33 . In patients at risk to develop severe OHSS with less than 20 oocytes retrieved following the ultra-short fl are GnRH agonist/GnRH antagonist protocol, GnRH agonist trigger has been off ered recently with an intensive luteal support and 1500 IU of hCG in order to improve IVF outcome while eliminating OHSS 34 . Although the induction of fi nal follicular maturation using GnRH agonist with its advantages over hCG trigger represents a paradigm shift in the ovulation triggering concept in ART, kisspeptins have also been shown to eff ectively elicit an LH surge, which suggests a completely new, 'natural' pharmacological option and as a new trigger concept 35 . It seems that the risk of OHSS development may be even more decreased following kisspeptin trigger comparing to GnRH agonist, but it is highly speculative because no study so far has been performed in an OHSS risk population and therefore its safety and effi cacy remains to be determined 3 .
GnRH Antagonist Protocols
Gonadotropin-releasing hormone antagonists directly and rapidly inhibit gonadotropin release during COS within several hours without hypo-estrogenic side eff ects, fl are-up or long down-regulation and higher OHSS incidence as compared to GnRH agonists. Th ree diff erent protocol regimens have been used including multiple-dose fi xed (0.25 mg daily from day six or seven of COS) or fl exible (0.25 mg daily when leading follicle is 14 to 15 mm) and single-dose regimen (3 mg on day 7 to 8 of stimulation) protocols, with or without the addition of an oral contraceptive pill. Although the probability of clinical pregnancy with GnRH antagonists initially seemed lower than with GnRH agonists, more recent studies were unable to provide any evidence for a diff erence in the live birth rates by using GnRH antagonists as compared to long GnRH agonist protocols. According to an update of a Cochrane review and forty-fi ve RCTs, the use of GnRH antagonist compared with long GnRH agonist protocols was associated with a signifi cantly lower incidence of OHSS and there was no evidence for a difference in live birth rates [36] [37] [38] . Comparing the eff ectiveness and safety of GnRH antagonist and GnRH agonist long protocol in supposedly normal ovarian responders undergoing IVF, results of a recent meta--analysis show that the number of stimulation days, gonadotropin amount, E2 value on the day of hCG, number of oocytes retrieved and incidence of OHSS were signifi cantly lower with the GnRH antagonist protocol, whereas the ongoing pregnancy and live birth rates were similar in the two groups 39 . Evaluating the outcomes of IVF utilization of GnRH antagonists for ovarian stimulation in PCOS patients compared with long agonist protocols, the clinical pregnancy rate was similar in the two groups, whereas for severe OHSS, a GnRH antagonist protocol was signifi cantly better in PCOS patients 40, 41 .
Dopamine Agonists
In a rat ovarian hyperstimulation model, it was demonstrated that low-dose dopamine agonist administration blocked VEGF-mediated vascular hyperpermeability without altering VEGF receptor(r) 2-dependent luteal angiogenesis 42 . Targeting the VEGF/ VEGFR2 pathway by the administration of pharmacotherapy through low doses of dopamine agonists might be the most appropriate way to prevent OHSS in high-risk patients. Th e proposed mode of action appears to be through partial blockage of VEGFR2 specifi c phosphorylation sites involved in the development of vascular permeability without aff ecting tyrosine sites or activating angiogenic activity 43 . It is likely that decreased VEGF secretion leads to less VEGFR2 activation and lower amounts of phosphorylated VEGFR2 resulting in inhibition of increased vascular permeability and OHSS prevention 44 . According to guidelines for the use of dopamine agonist, its use should be considered in patients at high risk of OHSS by the presence with one or more of the following fi ndings: >20 growing follicles of more than 12 mm in diameter; E2 >3000 pg/mL; and in patients with a history of previous OHSS even without evident signs of high ovarian response. It would be preferable to start with the treatment a few hours before the injection of hCG, to enable the presence of dopamine agonists before the rise in VEGF production. Cabergoline is currently used at a daily dose of 0.5 mg for eight days despite its long half-life (65-69 h) because it is the best known eff ective regimen with good tolerability, in addition to rectal bromocriptine at a daily dose of 2.5 mg for sixteen days as an alternative 45 . In hyperstimulated women undergoing ART, cabergoline successfully reduces hemoconcentration and ascites as a well-established and safe medication in the prevention of OHSS 46 . Although cabergoline is probably not as eff ective as replacing hCG with a GnRH agonist for decreasing the incidence of OHSS, it can be used as a secondary prevention measure for women at high risk of OHSS undergoing ART and it appears to reduce the risk of the syndrome, especially moderate OHSS. In addition, cabergoline reduces the occurrence of moderate-severe OHSS with no relevant negative effects on the number of retrieved oocytes or implantation rates and clinical pregnancy, without deleterious impact on pregnancy outcome 47, 48 . Moreover, evaluating the long-term eff ects of prophylactic treatment with cabergoline, no negative impact on live birth rates and miscarriage rates without increased rate of congenital malformations of the babies born has been observed 49, 50 . Quinagolide used in a fi xed regimen of three oral doses (50, 100 and 200 μg/day), starting on the day of hCG and continued for 17-21 days, signifi cantly reduces the frequency of moderate/severe early OHSS (12% vs. 13% vs. 4%) as compared with placebo (23%), without compromising pregnancy or treatment outcome. Although the 200-μg dose of quinagolide was most eff ective in preventing moderate/severe early OHSS in IVF patients, this dose was associated with poor tolerability when administered without dose titration, but also lower doses of quinagolide may be effi cacious. Th e treatment eff ect is more marked in patients that did not achieve clinical pregnancy and therefore it may be more suitable for oocyte donors or for patients with postponed embryo transfer. However, if quinagolide is used at high doses without dose titration, it is associated with poor tolerability, although the incidence of deleterious events declines after the initial days of treatment 51 . Bromocriptine is the next dopamine agonist after cabergoline which evokes interest in recent years, owing to its advantages in patients at risk of OHSS, including its shorter half-life and greater experience with this drug in pregnancy, the lack of teratogenicity, despite side eff ects such as nausea, headaches and orthostatic dysregulation. Th e incidence of clinically signifi cant OHSS was signifi cantly lower (17.5%) as compared to controls (40.9%) due to the benefi cial effect of bromocriptine 2.5 mg for rectal insertion, starting on the day of ovum pick up for a period of sixteen days, with no diff erences between the groups in clinical pregnancy rates 52 . Although according to a recent meta-analysis the use of dopamine agonists appears to be useful for the prevention, but less eff ective for the treatment of OHSS, yet so far, no conclusions can be made as for when to start and stop treatment, the most eff ective drug, the optimal dose, or the most appropriate drug regimen 53 . However, in the light of the new pathogenic and pharmacological evidence, currently dopamine agonists should defi nitely be considered for prevention of both early and late OHSS. Future prospective randomized studies should compare diff erent modalities in women at high risk of OHSS 54 .
Mild Stimulation Protocols
Mild ovarian stimulation for IVF uses a low dosage of gonadotropins (100-150 IU), which usually starts in the early follicular phase in combination with a GnRH antagonist fi ve to seven days of stimulation to produce a maximum of ten oocytes. However, minimal stimulation refers to the use of a sequential administration of clomiphene citrate (CC) followed by low-dose gonadotropins and a GnRH antagonist that yields a maximum of fi ve oocytes, with a range from one to fi ve. Both stimulations off er an attractive option to reduce the incidence of OHSS in patients who have experienced this complication in a previous treatment cycle or in high-responders 55 . However, there is only moderate-quality evidence that mild stimulation reduces OHSS without producing a clinically relevant diff erence in clinical pregnancy rates 8 . Since recently, scientifi c interest has been increasingly focused on mild approaches for ovarian stimulation in clinical practice because mild stimulations are more physiological, aiming to develop safer and more patientfriendly protocols, less drug use, lower costs and decreased risks of treatment, especially OHSS. A lower incidence of OHSS (4.7%) was observed in patients with a mild/minimal stimulation protocol of recombinant FSH combined with GnRH antagonist than in patients with a standard long protocol (8.4%). Although a signifi cantly higher pregnancy rate (37.7% vs. 23.4%) and delivery rate (32.8% vs. 20.1%) were observed in favor of patients with mild stimulation compared to conventional long down-regulation regimen, these data are not evidence based 56 . Comparing the eff ectiveness of mild ovarian stimulation with GnRH-antagonist and long protocol with low-dose FSH in young, normo-ovulatory responders undergoing IVF, the incidence of severe OHSS, as well as pregnancy and implantation rates were comparable with the two regimens 57 . Furthermore, there was no evidence indicating that minimal stimulation regimens diff ered signifi cantly from gonadotropins in GnRH agonist protocols in terms of OHSS incidence and live births or pregnancy rates. According to fi ndings from a Cochrane analysis, the use of CC with gonadotropins (with or without mid-cycle antagonist) led to a reduction in the incidence of OHSS varying between 0.8% and 1.8%, compared with 3.5% preva- Casper et al. 12 Engmann et al. 14 Gülekli et al. 16 Humaidan et al. 21 Griesenger et al. 22 Fatemi et al. 45 Tang et al. 47 Leitao et al. 48 Youssef et al. 49 Alvarez et al. 50 Busso et al. 51 Baumgarten et al. Nastri et al. 8 Zarek et al. 55 Rinaldi et al. 56 Casano et al. 57 Gibrel et al. 58 Figueiredo et al. 59 Mild ovarian response Less drug use and lower cost Lower incidence of OHSS Satisfactory pregnancy rates and pregnancy outcome
Higher risk of miscarriage rates is correlated with poor ovarian response comparing to hyperresponse to ovarian stimulation Moderate OHSS = ovarian hyperstimulation syndrome; LH = luteinizing hormone; GnRH = gonadotropin-releasing hormone; ET = embryo transfer; CC = clomiphene citrate lence of OHSS using a GnRH agonist regimen 58 . It is likely that CC with gonadotropin and GnRH antagonist decreases the risk of OHSS because in a recent meta-analysis there was a signifi cant reduction in OHSS (0.5%) as compared with conventional controlled ovarian hyperstimulation (4.1%) 59 (Table 1) .
Conclusion
Although among currently available medical strategies none is completely eff ective, there is high-quality evidence that replacing hCG by GnRH agonists and moderate-quality evidence that antagonist protocols, dopamine agonists and protocols with a mild ovarian response reduce the occurrence of OHSS. GnRH agonist trigger is the best tool for OHSS prevention due to signifi cant decrease in the incidence of OHSS, however, the use of intensive steroidal luteal support or low-dose hCG is required to achieve optimal conception rates. Th e incidence of OHSS was signifi cantly lower in the GnRH antagonist protocol than in GnRH agonist long regimen, whereas live birth rates were similar in the two groups. Among dopamine agonists used, cabergoline, quinagolide and bromocriptine are the most common drugs that should be considered for OHSS prevention, especially for moderate forms of the syndrome, without adverse eff ects on pregnancy outcome. Furthermore, protocols with a mild ovarian response represent an attractive option to reduce the incidence of OHSS in patients who have experienced this complication in a previous treatment cycle or in high-responders with satisfactory pregnancy outcome.
